Inactive Instrument

Highlights Signal Genetics Inc Nasdaq

Equities

US8266401046

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 16	Foghorn Therapeutics Names Kristian Humer CFO	MT
Mar. 21	B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000	Feb. 27	MT
Viridian Therapeutics, Inc. Provides Key Updates on its Anti-Insulin-Like Growth Factor 1 Receptor (IGF-1R) Programs in Thyroid Eye Disease and its Programs Targeting FcRn	Jan. 08	CI
Viridian Therapeutics Q3 Loss Widens, Revenue Drops	Nov. 13	MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q3 Revenue $72,000	Nov. 13	MT
Ypsomed to Customize, Supply Autoinjector Pen Device for Viridian Therapeutics	23-10-26	MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q2 Revenue $72,000	23-08-08	MT
Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease	23-07-10	CI
Viridian Therapeutics Q1 Loss Widens, Revenue Declines	23-05-10	MT
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $98,000	23-05-09	MT
Viridian Therapeutics Partners With Drug Delivery Innovator Enable Injections	23-05-08	MT
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections	23-05-08	CI
Viridian Therapeutics' Q4 Loss Narrows, Revenue Falls	23-03-08	MT
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q4 Revenue $105,000	23-03-08	MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Signal Genetics Inc Nasdaq

Equities

US8266401046

Highlights

Filters